Trade BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company based in Durham, North Carolina. The company is a late-stage biotechnology company that focuses on oral medicines for rare and serious diseases. The antiviral drug BioCryst RAPIVAB was approved by the FDA in December 2014. It has also been approved in Japan, Korea and China. The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial IPO listing its shares on nasdaq. In 2008 the company was selected as one of the fastest growing companies by Deloitte and Touche in its 2008 list of fast technology 500.In October 2010, bioCryst announced its headquarters will move to Durham, North Carolina, where the company has had an office since 2006. BioCryst Pharmaceuticals discovers a novel, oral small molecule drugs that treat rare diseases that have significant unmet medical needs and enzyme plays a key role in the biological course of the disease. BioCryst's core development programs include: